Adult Dosing
Neovascular age-related macular degeneration
- 0.5 mg intravitreal injection every month
- May decrease to 0.5 mg q3 months after four injections
Macular edema following retinal vein occlusion (RVO)
- 0.5 mg intravitreal injection every month (approximately 28 days) for 6 months
Diabetic macular edema (DME)
- 0.3 mg (0.05 mL of 6 mg/mL solution) intravitreal injection once a month
Notes- Intravitreal injection procedure should be carried out under controlled aseptic conditions
- Adequate anesthesia and a broad-spectrum microbicide should be initiated before administration of ranibizumab
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
- Monitor intraocular pressure and perfusion of the optic nerve head following intravitreous injection as increases in IOP have been noted within 60 minutes of intravitreal injection
- Endophthalmitis and retinal detachments may occur following intravitreal injections. Monitor during the 1st week following the injection for identifying possible infections
- Arterial thromboembolic events following intravitreal use have been reported
- Fatal events occurred more frequently in DME patients treated monthly with ranibizumab than with control
Caution: Use cautiously in
Pregnancy Category:C
Breastfeeding: Safety unknown. Because many drugs are excreted in human milk and because there is a potential for adverse effects in breastfed infants, caution should be exercised when administered to a nursing woman.
